Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PM647a

Other · developed by Prime Medicine

Phase 1/2 Most advanced trial
PRME Developer
1 Registered trials

What is PM647a?

PM647a is being studied in participants with alpha-1 antitrypsin deficiency caused by a homozygous Pi*Z allele (Pi*ZZ genotype), including those with lung or liver involvement.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
Prime Medicine, Inc. (PRME)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07887347 Phase 1/2 Alpha-1 Antitrypsin Deficiency Not yet recruiting PRME

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AATDAlpha-1 Antitrypsin DeficiencyAlpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin Deficiency-associated Lung Disease

More from Prime Medicine

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRME page.

Follow PRME, the company behind PM647a

See PRME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRME catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.